Correlation Between Larimar Therapeutics and Sutro Biopharma

Can any of the company-specific risk be diversified away by investing in both Larimar Therapeutics and Sutro Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Larimar Therapeutics and Sutro Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Larimar Therapeutics and Sutro Biopharma, you can compare the effects of market volatilities on Larimar Therapeutics and Sutro Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Larimar Therapeutics with a short position of Sutro Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Larimar Therapeutics and Sutro Biopharma.

Diversification Opportunities for Larimar Therapeutics and Sutro Biopharma

0.94

Correlation Coefficient

Larimar Therapeutics  Sutro Biopharma

Almost no diversification

The 3 months correlation between Larimar and Sutro is 0.94. Overlapping area represents the amount of risk that can be diversified away by holding Larimar Therapeutics and Sutro Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sutro Biopharma and Larimar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Larimar Therapeutics are associated (or correlated) with Sutro Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sutro Biopharma has no effect on the direction of Larimar Therapeutics i.e., Larimar Therapeutics and Sutro Biopharma go up and down completely randomly.

Pair Corralation between Larimar Therapeutics and Sutro Biopharma

Given the investment horizon of 90 days Larimar Therapeutics is expected to under-perform the Sutro Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Larimar Therapeutics is 1.0 times less risky than Sutro Biopharma. The stock trades about -0.49 of its potential returns per unit of risk. The Sutro Biopharma is currently generating about -0.23 of returns per unit of risk over similar time horizon. If you would invest  207.00  in Sutro Biopharma on October 17, 2024 and sell it today you would lose (35.00) from holding Sutro Biopharma or give up 16.91% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

Larimar Therapeutics  vs.  Sutro Biopharma

Larimar Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Larimar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Sutro Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sutro Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Larimar Therapeutics and Sutro Biopharma

The main advantage of trading using opposite Larimar Therapeutics and Sutro Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Larimar Therapeutics position performs unexpectedly, Sutro Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will offset losses from the drop in Sutro Biopharma's long position.

The idea behind Larimar Therapeutics and Sutro Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.